文献速递淋巴瘤

Camidanlumab tesirine治疗复发或难治性淋巴瘤的1期剂量爬坡与扩展研究

Camidanlumab tesirine in patients with relapsed or refractory lymphoma: a phase 1, open-label, multicentre, dose-escalation, dose-expansion study.
PubMed 文献 · Lancet Haematol · 2021-01-01

这项1期多中心试验评估了抗CD25抗体药物偶联物camidanlumab tesirine在复发或难治性经典型霍奇金淋巴瘤和非霍奇金淋巴瘤患者中的安全性、耐受性和抗肿瘤活性。研究纳入133例患者,未达到最大耐受剂量,经典型霍奇金淋巴瘤患者总体缓解率为71%(95%CI 60-81),结果支持进一步评估该药。

要点

  • Camidanlumab tesirine在复发或难治性淋巴瘤中显示出抗肿瘤活性,经典型霍奇金淋巴瘤缓解率较高。
  • 推荐扩展剂量:经典型霍奇金淋巴瘤30 μg/kg和45 μg/kg,T细胞非霍奇金淋巴瘤80 μg/kg。
  • 常见≥3级治疗中出现的不良事件包括γ-谷氨酰转移酶升高、斑丘疹和贫血。

核心结论

  • Camidanlumab tesirine在复发或难治性淋巴瘤中显示出抗肿瘤活性,尤其经典型霍奇金淋巴瘤,值得进一步评估。

研究设计与样本

  • 1期、开放标签、多中心、剂量爬坡(第1部分)和剂量扩展(第2部分)试验,在12个医院站点(美国7个、英国5个)进行。
  • 纳入133例成人(≥18岁)病理确诊的复发或难治性经典型霍奇金淋巴瘤或非霍奇金淋巴瘤患者,ECOG体能状态0-2。
  • Camidanlumab tesirine静脉给药(3-150 μg/kg),每3周一次。

主要发现

  • 在86例可评估患者中,5例(6%)报告8例次剂量限制性毒性,未达到最大耐受剂量。
  • 133例患者中,≥10%患者报告的≥3级治疗中出现的不良事件包括γ-谷氨酰转移酶升高(20例[15%])、斑丘疹(16例[12%])和贫血(15例[11%])。
  • 74例(56%)患者发生严重治疗中出现的不良事件,最常见为发热(16例[12%])。
  • 经典型霍奇金淋巴瘤患者总体缓解率为71%(95%CI 60-81)。

关键数值与推荐

  • 推荐扩展剂量:经典型霍奇金淋巴瘤为30 μg/kg和45 μg/kg,T细胞非霍奇金淋巴瘤为80 μg/kg。
  • B细胞非霍奇金淋巴瘤未定义推荐扩展剂量。

临床怎么用

  • 该药可能成为复发或难治性淋巴瘤,尤其是经典型霍奇金淋巴瘤的潜在治疗选择,需进一步研究确认。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Novel approaches are required to improve outcomes in relapsed or refractory classical Hodgkin lymphoma and non-Hodgkin lymphoma. We aimed to evaluate camidanlumab tesirine, an anti-CD25 antibody-drug conjugate, in this patient population. METHODS: This was a phase 1, dose-escalation (part 1), dose-expansion (part 2), multicentre trial done in 12 hospital sites (seven in the USA and five in the UK). Adults (≥18 years old) with pathologically confirmed relapsed or refractory classical Hodgkin lymphoma or non-Hodgkin lymphoma, an Eastern Cooperative Oncology Group performance status 0-2, who had no therapies available to them with established clinical benefit for their disease stage were enrolled. Camidanlumab tesirine was administered intravenously (3-150 μg/kg) once every 3 weeks. Primary objectives were to assess dose-limiting toxicity, determine maximum tolerated dose and recommended expansion dose(s), and assess safety of camidanlumab tesirine. Safety was assessed in all treated patients; antitumour activity was assessed in patients with one or more valid baseline and post-baseline disease assessment and in those who had disease progression or died after first study-drug dose. This trial was registered with ClinicalTrials.gov, NCT02432235. FINDINGS: Between Oct 5, 2015, and Jun 30, 2019, 133 patients were enrolled (77 [58%] had classical Hodgkin lymphoma and 56 (42%) had non-Hodgkin lymphoma). Median follow-up was 9·2 months (IQR 4·2-14·3). Eight dose-limiting toxicities were reported in five (6%) of 86 patients who were evaluable; the maximum tolerated dose was not reached. The recommended doses for expansion were 30 μg/kg and 45 μg/kg for patients with classical Hodgkin lymphoma and 80 μg/kg for patients with T-cell non-Hodgkin lymphomas. No recommended doses for expansion were defined for B-cell non-Hodgkin lymphomas. Grade 3 or worse treatment-emergent adverse events (reported by ≥10% of the 133 patients) included increased γ-glutamyltransferase (20 [15%] patients), maculopapular rash (16 [12%]), and anaemia (15 [11%]); 74 (56%) patients had serious treatment-emergent adverse events, most commonly pyrexia (16 [12%]). One (1%) fatal treatment-emergent adverse event and two (2%) deaths outside the reporting period were considered at least possibly study-drug related. Antitumoural activity was seen in classical Hodgkin and non-Hodgkin lymphomas; notably in all patients with classical Hodgkin lymphoma, the overall response was 71% (95% CI 60-81). INTERPRETATION: These results warrant evaluation of camidanlumab tesirine as a potential treatment option for relapsed or refractory lymphoma, particularly in patients with classical Hodgkin lymphoma. FUNDING: ADC Therapeutics.

来源:Lancet Haematol,查看原文。版权归原作者所有。

引用

  1. Hamadani M, Collins GP, Caimi PF, et al. Camidanlumab tesirine in patients with relapsed or refractory lymphoma: a phase 1, open-label, multicentre, dose-escalation, dose-expansion study. Lancet Haematol. 2021. PMID: 34048682. doi:10.1016/S2352-3026(21)00103-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。